Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia

Stansfield, LC; Pollyea, DA

Stansfield, LC (reprint author), Denver Hlth, Serv Pharm, 790 Delaware St, Denver, CO 80204 USA.

PHARMACOTHERAPY, 2017; 37 (12): 1586

Abstract

Acute myeloid leukemia (AML), a clonal hematologic malignancy that results in bone marrow failure, is the most common acute leukemia in adults (median......

Full Text Link